BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 37175943)

  • 1. Novel Susceptibility Genes Drive Familial Non-Medullary Thyroid Cancer in a Large Consanguineous Kindred.
    Majdalani P; Yoel U; Nasasra T; Fraenkel M; Haim A; Loewenthal N; Zarivach R; Hershkovitz E; Parvari R
    Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37175943
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole exome and target sequencing identifies MAP2K5 as novel susceptibility gene for familial non-medullary thyroid carcinoma.
    Ye F; Gao H; Xiao L; Zuo Z; Liu Y; Zhao Q; Chen H; Feng W; Fu B; Sun L; Jiang X; He D; Jiang H; Yang M; Li L; Chen F; Liu X; Li S; Li Z; Jiang Y; Cheng L; Bu H
    Int J Cancer; 2019 Mar; 144(6):1321-1330. PubMed ID: 30132833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Familial non-medullary thyroid cancer: unraveling the genetic maze.
    Peiling Yang S; Ngeow J
    Endocr Relat Cancer; 2016 Dec; 23(12):R577-R595. PubMed ID: 27807061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current Knowledge of Germline Genetic Risk Factors for the Development of Non-Medullary Thyroid Cancer.
    Hińcza K; Kowalik A; Kowalska A
    Genes (Basel); 2019 Jun; 10(7):. PubMed ID: 31247975
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Greek family with a follicular variant of familial papillary thyroid carcinoma: TCO, MNG1, fPTC/PRN, and NMTC1 excluded as susceptibility loci.
    Tsilchorozidou T; Vafiadou E; Yovos JG; Romeo G; McKay J; Lesueur F; Bonora E
    Thyroid; 2005 Dec; 15(12):1349-54. PubMed ID: 16405407
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A Familial Non Medullary Thyroid Carcinoma (FNMTC) : a clinical and genetic update].
    Valdes-Socin H; Palmeira L; Burlacu MC; Daly AF; Bours V; Beckers A
    Rev Med Liege; 2016 Dec; 71(12):557-561. PubMed ID: 28387096
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Familial non-medullary thyroid cancer: a critical review.
    Capezzone M; Robenshtok E; Cantara S; Castagna MG
    J Endocrinol Invest; 2021 May; 44(5):943-950. PubMed ID: 33025555
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnosis and Management of Hereditary Thyroid Cancer.
    Bano G; Hodgson S
    Recent Results Cancer Res; 2016; 205():29-44. PubMed ID: 27075347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a novel germline FOXE1 variant in patients with familial non-medullary thyroid carcinoma (FNMTC).
    Pereira JS; da Silva JG; Tomaz RA; Pinto AE; Bugalho MJ; Leite V; Cavaco BM
    Endocrine; 2015 May; 49(1):204-14. PubMed ID: 25381600
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An update on familial nonmedullary thyroid cancer.
    Ammar SA; Alobuia WM; Kebebew E
    Endocrine; 2020 Jun; 68(3):502-507. PubMed ID: 32162184
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genetic Mutations and Variants in the Susceptibility of Familial Non-Medullary Thyroid Cancer.
    Miasaki FY; Fuziwara CS; Carvalho GA; Kimura ET
    Genes (Basel); 2020 Nov; 11(11):. PubMed ID: 33218058
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical and Genetic Features of a Large Monocentric Series of Familial Non-Medullary Thyroid Cancers.
    Cirello V; Colombo C; Karapanou O; Pogliaghi G; Persani L; Fugazzola L
    Front Endocrinol (Lausanne); 2020; 11():589340. PubMed ID: 33488516
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HABP2 G534E Mutation in Familial Nonmedullary Thyroid Cancer.
    Zhang T; Xing M
    J Natl Cancer Inst; 2016 Jun; 108(6):djv415. PubMed ID: 26832773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CHEK2 germline variants identified in familial nonmedullary thyroid cancer lead to impaired protein structure and function.
    Pires C; Marques IJ; Valério M; Saramago A; Santo PE; Santos S; Silva M; Moura MM; Matos J; Pereira T; Cabrera R; Lousa D; Leite V; Bandeiras TM; Vicente JB; Cavaco BM
    J Biol Chem; 2024 Mar; 300(3):105767. PubMed ID: 38367672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BROX haploinsufficiency in familial nonmedullary thyroid cancer.
    Pasquali D; Torella A; Accardo G; Esposito D; Del Vecchio Blanco F; Salvatore D; Sabatino P; Pacini F; Barbato F; Castagna MG; Cantara S; Nigro V
    J Endocrinol Invest; 2021 Jan; 44(1):165-171. PubMed ID: 32385852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of
    Marques IJ; Gomes I; Pojo M; Pires C; Moura MM; Cabrera R; Santos C; van IJcken WFJ; Teixeira MR; Ramalho JS; Leite V; Cavaco BM
    Thyroid; 2021 Sep; 31(9):1366-1375. PubMed ID: 33906393
    [No Abstract]   [Full Text] [Related]  

  • 17. Penetrance of a rare familial mutation predisposing to papillary thyroid cancer.
    Saporito D; Brock P; Hampel H; Sipos J; Fernandez S; Liyanarachchi S; de la Chapelle A; Nagy R
    Fam Cancer; 2018 Jul; 17(3):431-434. PubMed ID: 29027612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genetic predisposition to papillary thyroid cancer.
    Kula D; Kalemba M; Jurecka-Lubieniecka B; Puch Z; Kowalska M; Tyszkiewicz T; Kowal M; Handkiewicz-Junak D
    Endokrynol Pol; 2010; 61(5):486-9. PubMed ID: 21049463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HABP2 germline variants are uncommon in familial nonmedullary thyroid cancer.
    Weeks AL; Wilson SG; Ward L; Goldblatt J; Hui J; Walsh JP
    BMC Med Genet; 2016 Aug; 17(1):60. PubMed ID: 27530615
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of susceptibility gene mutations associated with the pathogenesis of familial nonmedullary thyroid cancer.
    Zhu J; Wu K; Lin Z; Bai S; Wu J; Li P; Xue H; Du J; Shen B; Wang H; Liu Y
    Mol Genet Genomic Med; 2019 Dec; 7(12):e1015. PubMed ID: 31642198
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.